Medtronic spinout Inspire Medical lands FDA win for 1st sleep apnea implant
Report: FDA panel recommends Inspire Medical’s sleep apnea implant
Updated February 24, 2014, with details from Inspire Medical.
An expert panel of FDA advisors voted today to recommend approval for Inspire Medical’s sleep apnea implant, the Inspire II Upper Airway Stimulator, the company confirmed.
FDA reviews adverse events, durability of Inspire Medical’s sleep apnea implant
Minnesota-based Inspire Medical Systems has a date with the FDA tomorrow, when the agency’s expert Anesthesiology & Respiratory Therapy Devices Panel will review data and make a recommendation on the Inspire II Upper Airway Stimulator.
FDA to review Inspire Medical’s sleep apnea implant
Inspire Medical Systems is getting the FDA treatment, landing a date next month with the Anesthesiology & Respiratory Therapy Devices panel to undergo review of the company’s implanted Inspire II Upper Airway Stimulator for treatment of obstructive sleep apnea.
InspireMed pulls in new VP of corporate development from Covidien | Personnel Moves
Medtronic spinout Inspire wins CE Mark for apnea device
Medtronic Inc. (NYSE:MDT) spinout Inspire Medical Systems Inc. received the go-ahead from regulators to sell its obstructive sleep apnea device in Europe and test it for the U.S. market.
CE Mark approval in hand, the Maple Grove, Minn.-based device developer expects to mount a market development push for its Inspire upper airway stimulation therapy in Europe near year-end 2011.
MassDevice Network
@MassDevice
LinkedIn
YouTube